Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region-Reference-Cited by-同舟云学术

Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Published:2020-09-21 Issue:10 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Johnston Brian D.¹²^ORCID,Thuras Paul¹²,Porter Stephen B.¹,Anacker Melissa³,VonBank Brittany³,Snippes Vagnone Paula³,Witwer Medora³,Castanheira Mariana⁴,Johnson James R.¹²

Affiliation:

1. Minneapolis VA Health Care System, Minneapolis, Minnesota, USA

2. University of Minnesota, Minneapolis, Minnesota, USA

3. Minnesota Department of Health, St. Paul, Minnesota, USA

4. JMI Laboratories, North Liberty, Iowa, USA

Abstract

Emerging carbapenem resistance in Escherichia coli , including sequence type 131 (ST131), the leading cause of extraintestinal E. coli infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV), plus 11 comparators, against 343 carbapenem-resistant (CR) clinical E. coli isolates, then compared susceptibility results with bacterial characteristics and region.

Funder

Tetraphase Pharmaceuticals

Biomedical Laboratory Research and Development, VA Office of Research and Development

Shionogi

Allergan

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00797-20

Reference34 articles.